The FDA's approval of lecanemab and donanemab raise many questions, including about some potentially shady behavior, according to investigative journalists Jeanne Lenzer and Shannon Brownlee. My latest for @ahcj.bsky.socialhealthjournalism.org/blog/2024/10...

Reporters uncover conflicts and dubious data on latest Alzheimer’s drug

A blockbuster story in The BMJ showed major concerns surrounding the approval process, efficacy and safety of the Alzheimer’s drug donanemab.

Liz, I wanted to suggest a story idea: "Are Blood Biomarkers Accurate in Diagnosing Alzheimer's?" Please let me know your preferences so I can send over more information if you're interested.